Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision
Posted inGastroenterology General Surgery news

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision

Researchers have developed the Liver Immune Frailty Index (LIFI), a biomarker-based tool using fractalkine and MMP3 to predict post-liver transplant mortality. With a C-statistic of 0.83, LIFI identifies high-risk candidates, potentially transforming preoperative risk stratification and perioperative management.
Redefining Post-Cardiac Arrest Care: Two-Year TTM2 Data Confirm No Long-Term Advantage for Targeted Hypothermia
Posted inCardiology Critical Care news

Redefining Post-Cardiac Arrest Care: Two-Year TTM2 Data Confirm No Long-Term Advantage for Targeted Hypothermia

This 2-year follow-up of the TTM2 trial demonstrates that targeted hypothermia at 33°C provides no long-term benefit for functional or cognitive recovery compared to targeted normothermia. The findings emphasize the importance of early fever management and suggest a recovery plateau after six months post-arrest.
Long-Term Ublituximab Therapy in Multiple Sclerosis: Five-Year Results from the ULTIMATE I and II Extension Study Validate Early High-Efficacy Intervention
Posted inNeurology news

Long-Term Ublituximab Therapy in Multiple Sclerosis: Five-Year Results from the ULTIMATE I and II Extension Study Validate Early High-Efficacy Intervention

Five-year data from the ULTIMATE I and II open-label extension demonstrate that ublituximab maintains exceptionally low relapse rates and slows disability progression in relapsing multiple sclerosis, emphasizing the clinical superiority of early and sustained B-cell depletion therapy.